1480 PERCUTANEOUS CT AND US GUIDED RADIOFREQUENCY ABLATION OF RENAL MASSES: LONG TERM EFFICACY (2010)

You have accessJournal of UrologyKidney Cancer: Localized V1 Apr 20101480 PERCUTANEOUS CT AND US GUIDED RADIOFREQUENCY ABLATION OF RENAL MASSES: LONG TERM EFFICACY Timothy McClure, Daniel Chow, Allan Pantuck, Peter Schulam, Arie Belldegrun, David Lu, and Steven Raman Timothy McClureTimothy McClure More articles by this author , Daniel ChowDaniel Chow More articles by this author , Allan PantuckAllan Pantuck More articles by this author , Peter SchulamPeter Schulam More articles by this author , Arie BelldegrunArie Belldegrun More articles by this author , David LuDavid Lu More articles by this author , and Steven RamanSteven Raman More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1196AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To review our 5 year experience with percutaneous CT & US guided radiofrequency (RF) ablation of kidney masses and examine the feasibility, complications, and outcomes of RF ablation. METHODS After IRB approval, all records of patients who underwent percutaneous RF ablation for renal masses were reviewed between February 2004 and September 2009. RF ablation was performed with the Valleylab CC1 generator using single electrodes for lesions < 2 cm, double electrodes (2-3 cm) or triple electrodes for lesions > 3cm or central lesions. Following ablation, CT or MR was performed at baseline for residual disease, and then at 3-6 month intervals to determine rates of local & distant recurrence. A complete ablation was defined as absence of residual disease (i.e. enhancement or increasing size of ablation site) on post procedure imaging. Recurrence was defined as new enhancement or increasing size in a previous ablation site. RESULTS A total 106 RF ablations were attempted for 90 renal masses found in 63 patients. Mean renal mass size was 2.7 cm (0.9 cm – 8.1 cm). Mean patient follow up after a completed ablation was 20 months (median 18 months). Lesions completely ablated in a single attempt numbered 80/90 (89%) and the remainder were treated in two or more sessions. Recurrence occurred in 1/90 (1%) lesion. Mild complications were self limited and included 5/90 (5.6%) subclinical subscapular hematomas and 2/90 (2.2%) transient urine leaks. Major complications included post procedural hypoxia requiring intubation, 1/90 (1.1%) and UPJ strictures requiring nephrectomy, 2/90 (2.2%). Average change in GFR was –11.1 mg/DL. CONCLUSIONS Our single center study demonstrates that percutaneous RF ablation can reliably treat renal masses in a single attempt with minimal complications. In addition, completely ablated lesions show low rates of recurrence. In summary, percutaneous RF ablation is a promising and safe treatment option in the management of patients with renal masses. Los Angeles, CA© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e570 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Timothy McClure More articles by this author Daniel Chow More articles by this author Allan Pantuck More articles by this author Peter Schulam More articles by this author Arie Belldegrun More articles by this author David Lu More articles by this author Steven Raman More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...